Monoclonal Antibody to Spectrin beta 3 (Clone: ABM5A16)
|Amount :||100 µg|
|Isotype :||Mouse IgG2a, kappa|
|Purification :||Protein G Chromatography|
|Content :||25 µg in 50 µl/100 µg in 200 µl PBS containing 0.05% BSA and 0.05% sodium azide. Sodium azide is highly toxic.|
|Storage condition :||Store the antibody at 4°C, stable for 6 months. For long-term storage, store at -20°C. Avoid repeated freeze and thaw cycles.|
|Gene ID :||6712|
|Uniprot ID :||O15020|
|Alternative Name :||Spectrin beta chain, non-erythrocytic 2, Beta-III spectrin, Spinocerebellar ataxia 5 protein|
|Immunogen Information :||A partial length recombinant protein (a.a 1280-1450) of Spectrin beta 3 was used as the immunogen for this antibody.|
Beta-III spectrin is a protein encoded by the gene SPTBN2, spans 2390 amino acids and consists of an amino-terminal actin binding domain (ABD), a central region containing seventeen spectrin repeat domains, and a carboxy-terminal pleckstrin homology domain. It is critical for the correct development and maintenance of Purkinje cell dendritic structure. Beta-III spectrin is expressed predominantly in the brain and is enriched in cerebellar Purkinje cells. In addition, Beta-III spectrin participates in endomembrane trafficking through its interaction with the actin related protein, ARP1. The functional unit of Beta-III spectrin is considered to be a tetrameric complex composed of two Beta-spectrin subunits and two Alpha-II-spectrin subunits. Mutations in the gene encoding Beta-III spectrin give rise to spinocerebellar ataxia type 5, a neurodegenerative disease characterized by progressive thinning of the molecular layer, loss of Purkinje cells and increasing motor deficits.
WB: 0.1-0.5 µg/ml, FACS: 2-4 µg/10^6
For Research Use Only. Not for use in diagnostic/therapeutics procedures.
|Subcellular location:||Cytoplasm, Cytoplasm|
|Tissue Specificity:||Highly expressed in brain, kidney, pancreas, and liver, and at lower levels in lung and placenta.|
|BioGrid:||112590. 34 interactions.|